| Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. | |
| | |
MedLine Citation:
|
PMID: 20942636 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Lenalidomide has demonstrated clinical activity in myelodysplastic syndromes, particularly in patients with a deletion in the long arm of chromosome 5 (del[5q] abnormality). It has a direct effect on the del(5q) clone, which may contribute to its ability to induce cytogenetic responses. Lenalidomide also stimulates erythropoiesis, leading to erythroid responses in certain patients. Other effects include immunomodulation, anti-inflammatory effects and angiogenesis inhibition. New findings indicate that lenalidomide modulates key genes located within the del(5q) region, including tumor suppressor genes, and regulators of the actin cytoskeleton and cell membrane. Its effects on cytoskeleton regulation may explain its direct antitumor and immunomodulatory effects. This article provides an overview of the known effects of lenalidomide and new insights into its activity in del(5q) myelodysplastic syndromes. |
| | |
Authors:
|
Carla Heise; Troy Carter; Peter Schafer; Rajesh Chopra |
Related Documents
:
|
7573136 - Gonadal dysgenesis in del(18p) syndrome. 12843316 - Mutations at the sall4 locus on chromosome 20 result in a range of clinically overlappi... 19703806 - Cushing syndrome in a young woman due to primary pigmented nodular adrenal disease. 20574716 - Diagnosis and high incidence of hyperornithinemia-hyperammonemia-homocitrullinemia (hhh... 15950086 - Moyamoya syndrome in a child with down syndrome. 7733196 - Ocular findings in a family with sotos syndrome (cerebral gigantism). |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of anticancer therapy Volume: 10 ISSN: 1744-8328 ISO Abbreviation: Expert Rev Anticancer Ther Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-14 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101123358 Medline TA: Expert Rev Anticancer Ther Country: England |
Other Details:
|
Languages: eng Pagination: 1663-72 Citation Subset: IM |
Affiliation:
|
Department of Translational Development, Celgene Corporation, 1500 Owens St, Suite 600, San Francisco, CA 94158, USA. cheise@celgene.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Challenges of drug resistance in the management of pancreatic cancer.
Next Document: In vivo evaluation of novel chitosan graft polymeric micelles for delivery of paclitaxel.